Q4
19.8.2024 14:01:31 CEST | Business Wire | Press release
Q4 Inc. (“Q4” or “the company”), the IR Ops Platform, today announced it is a winner in the 2024 International Business Awards®. Honored for its “effectiveness in supporting client needs,” the company’s Web Content Services (WCS) team earned a bronze Stevie® Award for “Customer Service Team of the Year” — a category that spanned across industries — underscoring Q4’s commitment to delivering outstanding customer experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240819909828/en/
IBA Bronze Stevie Winner Badge (Graphic: Business Wire)
This is the second year in a row Q4 has been honored in the International Business Awards.
Considered “the Olympics for the workplace,” the International Business Awards (IBAs) are the world’s premier business awards program. All individuals and organizations worldwide – public and private, for-profit and non-profit, large and small — are eligible to submit nominations. The 2024 IBAs received entries from organizations in 62 nations and territories, with more than 3,600 nominations submitted.
Here’s what the judges had to say about Q4’s WCS team:
- “Their achievements reflect exceptional efficiency, accuracy, and client satisfaction.”
- “The team’s ability to handle client requests efficiently, maintain high accuracy, and achieve record CSAT scores highlights their effectiveness in supporting client needs.”
- “Q4’s core company values shine through in the way this team operates.”
- Q4’s WCS team shows “exceptional performance in customer service through impressive metrics, continuous improvement, and a commitment to customer satisfaction.”
- “The WCS team at Q4 has demonstrated outstanding performance.”
“IROs and their teams have a lot on their plates, and we want to alleviate that burden through our AI-driven IR Ops Platform,” said Darrell Heaps, Founder and CEO of Q4. “This recognition from the International Business Awards shows how our amazing Web Content Services team does just that. It also highlights the high-impact results our customers achieve — using Q4 to build investor relationships and make strategic decisions. As we continue to chart a bold, new path for investor relations, we’re committed to innovation that helps IR teams realize remarkable outcomes and frees up their time to focus on what matters: strategy, relationships, and driving premium valuations for their companies.”
Q4: A single, powerful platform for investor relations
Public companies today strive to maintain up-to-date, secure and compliant investor relations websites — so they can demonstrate what they do, attract investors, and motivate them to take action. Q4’s technology makes it easy for some of the world’s biggest brands — McDonald’s, Walmart, Visa, Netflix and many more — to create and manage IR websites that drive results, accelerate website updates (publishing changes within minutes, and 16 times faster than with other tools), streamline earnings management, and tap into real-time analytics on investor behavior. With decades of website design and IR experience, Q4’s award-winning WCS team provides further assistance with website development and change requests, as well as Q4 Platform support.
Websites are just one component of Q4’s holistic IR Ops Platform, an unprecedented and unified system for attracting investors, managing relationships and staying abreast of the market’s pulse. Rather than grapple with disparate and disconnected tools, IR leaders and their companies can access everything they need from a single place: using Q4 for IR websites, virtual events, an IR CRM, surveillance, engagement analytics and more, including secure AI for IR.
Q4’s win in the International Business Awards comes on the heels of other recent milestones and momentum for the company. Q4 has powered more than 18 million investor interactions and hosts 4,400 events annually — with 530,000+ investors connecting to events via the Q4 Platform each month. Named “Best Tech-Driven Capital Markets Platform” by Global Brands Magazine, Q4 serves more than 2,600 global clients, including half of the S&P 500.
About Q4 Inc.
Q4 Inc. is the first IR Ops Platform with the world’s largest set of proprietary investor data, purpose-built to remove obstacles between public companies and their investors. Q4 gives investor relations leaders and their teams the tools to attract, manage, and understand investors — all in one place. The AI-enabled Q4 IR Ops Platform boasts applications for website and event management, engagement analytics, and earnings lifecycle management, including AI Earnings Co-Pilot to generate draft scripts based on historical data, and AI earnings call summaries to understand peer sentiment. The Platform also includes a streamlined investor CRM and shareholder intelligence with enhanced metrics to elevate investor targeting strategies. Q4 delivers the data, insights, and workflows that give IR teams the power to focus on what really matters: strategy, relationships, and driving premium valuations for their companies.
The company is a trusted partner to more than 2,600 public companies globally, including many of the most respected brands in the world, and maintains an award winning culture where team members grow and thrive.
Q4 is headquartered in Toronto, with offices in London and Copenhagen. Learn more at www.q4inc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819909828/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
